{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:50Z","timestamp":1787010350801,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Radiation-induced thyroid dysfunction is very rarely associated with peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors using \u03b2-emitting radionuclides. With the emergence of \u03b1 radionuclide such as\n                    <jats:sup>225<\/jats:sup>\n                    Ac, PRRT using these radionuclides has shown better results; however, data on the toxicity profile are limited. This is a case report describing the thyroid dysfunction developed in a patient with inoperable metastatic neuroendocrine tumor with unknown primary after PRRT using\n                    <jats:sup>225<\/jats:sup>\n                    Ac-DOTATATE, which has never been reported previously.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000003893","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T18:11:20Z","timestamp":1631297480000},"page":"e184-e186","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Subclinical Hypothyroidism After 225Ac-DOTATATE Therapy in a Case of Metastatic Neuroendocrine Tumor"],"prefix":"10.1097","volume":"47","author":[{"given":"Anwin Joseph","family":"Kavanal","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Khosla","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"ii98","DOI":"10.1093\/jrr\/rrx054","article-title":"Radiation-related thyroid autoimmunity and dysfunction","volume":"59","year":"2018","journal-title":"J Radiat Res"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"e0200310","DOI":"10.1371\/journal.pone.0200310","article-title":"Pattern of radiation-induced thyroid gland changes in nasopharyngeal carcinoma patients in 48 months after radiotherapy","volume":"13","year":"2018","journal-title":"PLoS One"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000448398","article-title":"Painful radiation thyroiditis after 131I therapy for Graves\u2019 hyperthyroidism: clinical features and ultrasonographic findings in five cases","volume":"5","year":"2016","journal-title":"Eur Thyroid J"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"587065","DOI":"10.3389\/fendo.2020.587065","article-title":"Case report: primary hypothyroidism associated with lutetium 177-DOTATATE therapy for metastatic paraganglioma","volume":"11","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RLU.0000000000002915","article-title":"Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated \u03b2-emitter peptide receptor radionuclide therapy","volume":"45","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:07:35Z","timestamp":1750522055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003893"}},"subtitle":["Unknown Adverse Effect of PRRT"],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003893","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}